Aida Pharmaceuticals Inc. (OTC Bulletin Board: AIDA) today announced its recently-acquired research institute, the Jiangsu Institute of Microbiology Co. Ltd, is working toward the development of a new wide-spectrum antibiotic, Wetimicin, in the People’s Republic of China. The company believes Wetimicin will have a larger market volume than its current product, Etimicin Sulphate.
Wetimicin is part of the amino-glycoside family of antibiotics, and is being tested for its efficacy in the treatment of inflammation stemming from respiratory infection, urogenital infection, soft skin tissue infection, as well as trauma from operations and more.
Wetimicin’s stronger applicability to such a wide range of ailments supports JSIM scientists’ belief that the product may be more reliable for children and elderly patients than other products on the market.
Aida Pharmaceuticals launched research for the drug in 2000, and is currently working through Phase 1 clinical trials in conjunction with the Chinese government’s State Food and Drug Administration. The company anticipates Phase 2 testing will start sometime this year. Once approved by China’s SFDA, the company will have the right of first refusal regarding the manufacturing and marketing of the drug.
Let us hear your thoughts below: